SLC5A2 and heart failure: More specifically, SGLT2 inhibitors have been shown to reduce the risk of MACE and hospitalization for heart failure, slow the progression of kidney disease, and reduce cardiovascular and all-cause mortality in people with heart failure and renal impairment, regardless of diabetes status [135].